CUSIP NO. 483497103
This Amendment No. 5 to Schedule 13D (Amendment No. 5) amends the Schedule 13D originally filed with the Securities and Exchange
Commission (the Commission) on February 7, 2017 and amended by Amendment No. 1 filed with the Commission on March 2, 2017, Amendment No. 2 filed with the Commission on February 26, 2019, Amendment No. 3 filed with the Commission on March
20, 2019 and Amendment No. 4 filed with the Commission on April 3, 2019 (together, the Prior Filing), to disclose certain transactions in the Common Stock, par value $0.001 per share (the Common Stock), of KalVista
Pharmaceuticals, Inc. (the Issuer), including the disposition of some of the shares of the Issuers Common Stock held by Reporting Persons. Except as specifically amended by this Amendment No. 5, each Item of the Prior Filing
remains unchanged. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Prior Filing.
Item 1.
|
Security and Issuer.
|
This statement relates to the Common Stock, par value $0.001 per share (the Common Stock), of KalVista Pharmaceuticals, Inc. (the
Issuer). The address of the principal executive offices of the Issuer is 55 Cambridge Parkway, Suite 901E, Cambridge, Massachusetts 02142.
Item 2.
|
Identity and Background.
|
Item 2 of the Prior Filing is hereby amended and restated in its entirety as set forth below:
(a) This statement is filed by: (i) SV Life Sciences Fund IV, L.P. a Delaware limited partnership (SVLS IV LP) and SV
Life Sciences Fund IV Strategic Partners, L.P. a Delaware limited partnership (Strategic Partners and together with SVLS IV LP, the Funds), each direct owners of the shares of Common Stock of the Issuer (together, the
Shares); (ii) SV Life Sciences Fund IV (GP), L.P., a Delaware limited partnership (SVLS IV GP) and general partner of SVLS IV LP and Strategic Partners; and (iii) SVLSF IV, LLC, a Delaware limited liability company
and general partner of SVLS IV GP. Each of SVLS IV LP, Strategic Partners, SVLS IV GP and SVLSF IV, LLC are sometimes individually referred to herein as a Reporting Person and collectively as the Reporting Persons.
(b) The principal business address of the Reporting Persons is c/o SV Health Investors, One Boston Place, 201 Washington Street, Suite
3900, Boston, MA 02108. The principal business address of any person or entity listed on Schedule A annexed hereto is set forth on Schedule A annexed hereto.
(c) The principal business of the Reporting Persons is international life sciences venture capital investments. SVLS IV LP and Strategic
Partners are private venture capital funds. SVLS IV GP is the general partner of SVLS IV LP and Strategic Partners. SVLSF IV, LLC is the general partner of SVLS IV GP. The principal business of the persons or entities listed on Schedule A
annexed hereto is listed on Schedule A annexed hereto.
(d) No Reporting Person nor any person or entity listed on Schedule
A annexed hereto has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) No Reporting Person nor any person or entity listed on Schedule A annexed hereto has, during the last five years, been party
to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities
subject to, federal or state securities laws or finding any violation with respect to such laws.
(f) Each of the individuals listed
on Schedule A annexed hereto are citizens of the country set forth on Schedule A annexed hereto. Each of the Reporting Persons are organized under the laws of the State of Delaware.
6